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ABSTRACT

THE ADOPTION OF HARM REDUCTION BY ABSTINENCE PROGRAM STAFF:
A QUALITATIVE ANALYSIS

MAY 2016
MORGAN COE, B.A., EARLHAM COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor David R. Buchanan

Opioid overdose fatalities have quadrupled in the United States since the turn of the
century, and are becoming increasingly recognized as a nationwide epidemic. While naloxone
(narcan) has long been the standard treatment for overdose in clinical settings, it has not been
issued to opioid users or their family members in the U.S. until relatively recently. As naloxone
distribution and overdose training become more widespread, they are being incorporated into
more and more abstinence-oriented settings including detoxes, halfway houses, and outpatient
methadone and suboxone treatment programs. This qualitative study explored whether the staff
at such programs found that training their patients to use naloxone was disruptive or
controversial, and whether they found it difficult to reconcile these trainings’ basis in harm
reduction with their personal and organizational philosophies about substance use and recovery.
Ten subjects from Eastern and Central Massachusetts were interviewed about their experience
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introducing naloxone to their patients under the aegis of the Massachusetts Department of Public
Health’s Opioid Overdose Prevention Pilot Program, and their interviews were analyzed from a
descriptive phenomenological perspective. This approach seeks to distill the essence of a
phenomenon by analyzing the narratives of those who have experienced it, and has been found
especially useful when exploring questions that have not yet been studied in depth. The analysis
identified eleven recurring themes, grouped into four broad domains (What is overdose
prevention training? What is narcan? What is harm reduction? What is the goal of treatment?).
These themes suggested that while subjects overwhelmingly experienced naloxone distribution
and overdose prevention training as positive additions to their workplace, this experience did not
necessarily lead to more engagement with the broader concept of harm reduction.
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CHAPTER I
PROBLEM STATEMENT

Opiate users around the world have been found to have a mortality rate between 10 and
20 times that of the surrounding population (Hickman et al., 2003; Oppenheimer et al., 1994;
Perucci et al. 1991). The single largest cause of that mortality is overdose, which accounted for
26% of user deaths in Frischer’s (1993) Scottish study, 34% in Goldstein and Herrera’s (1995)
New Mexico study, and over half in Hickman’s (2003) London study. In Portland, Oregon
overdose was “a leading cause of death” in the year 1999 among all men aged 25–54 (Oxman
et al. 2000). Just as disturbingly, Hall & Darke (1998) found a six-fold increase in Australian
overdose mortality between 1979 and 1995. The Center for Disease Control and Prevention
(CDC/NCHS, 2015) reported that from 1999 to 2014, the U.S. drug overdose fatality rate more
than doubled (from 6.1 to 14.7 per 100,000 people), and the opioid overdose fatality rate more
than quadrupled (from 1.4 to 5.6 per 100,000). However, not all overdoses result in death: 38%
of Strang’s (1999) study participants had previously overdosed, as had 44% of Green’s (2008)
and 48% of Ochoa’s (2001). The rate at which participants had witnessed another user’s (not
necessarily fatal) overdose was considerably higher: 54% in Strang’s (1999) first study, 86% in
Darke’s (1996), 95% in Tobin’s (2009), and 97.4% in Strang’s (2000) later study. Clearly the
prevalence and potential consequences of opiate overdose represent significant public health
concerns, and perhaps one growing more serious with time. In 2014, 1.9 million Americans
suffered from prescription painkiller addiction, and approximately 586,000 were using heroin
(SAMHSA, 2015)
There are many ways to decrease the likelihood and impact of opiate overdose. These
options include: discouraging opiate use and increasing treatment and detox options,
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decreasing concomitant risk factors (such as concurrent alcohol or benzodiazepine use) among
opiate users, improving hospital and ambulance response to overdose, encouraging opiate
users to adopt non-injection methods of opiate intake, providing safer injection facilities with
medical staff, increasing the availability of maintenance treatment for opiate addicts, and
providing take-home naloxone to opiate users (Darke & Hall, 2003; Sporer, 1999). While each
of these options has certain advantages and disadvantages, the research proposed here focuses
on of the newest and least well-studied alternative—providing take-home naloxone to opiate
users.
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CHAPTER II
BACKGROUND

Naloxone has been used as an effective treatment for opiate overdose in clinical
settings since the early 1970s (World Health Organization, 1993). It functions as an opiate
antagonist, blocking the drug’s effects for a typical duration of 45-90 minutes. It takes effect
within 1-2 minutes at the most, and is considered to have only a very small chance of adverse
effects in patients (Baca & Grant, 2005; Galea et al., 2006; Kerr et al., 2008; Sporer, 1999).
Although naloxone is the standard treatment for overdose, it has not been issued to opiate users
(or their family members) for use outside of medical facilities until relatively recently. This
practice was begun as a component of European and Australian anti-overdose interventions in
the mid 90s, and was first adopted in the United States in 2001, when the San Francisco
Department of Public Health sponsored a pilot research program. In the same year, the state of
New Mexico implemented laws that freed physicians and private citizens from the legal
liabilities involved in having a drug prescribed to one person with the expectation that they
would use it on someone else, or have it used on them by someone else (Sporer & Kral, 2007).
There are currently naloxone training and distribution programs active in at least 30 U.S.
states, including Massachusetts (Wheeler et al., 2015).
In 2009, the greater Boston area led the nation in yearly drug- and heroin-related
emergency room admissions per 100,000 residents (SAMHSA, 2011), and since 2005 opioid
overdoses have surpassed automobile accidents as a cause of death in Massachusetts (Walley
et al., 2013). In 2007 there were 9.9 opiate-related deaths per 100,000 state residents,
compared to 5.2 in 1999 and 1.6 in 1990. In addition, there were 47 non-fatal hospitalizations
for every death, and the total cost for hospitalizations related to opioid dependence and
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overdose exceeded $239 million in 2007 (BSAS, 2009). In response to these rising rates of
fatal opiate overdose, the Massachusetts Department of Public Health created the Opioid
Overdose Prevention Pilot Program (OOPPP, or “Narcan Pilot Program” colloquially) in order
to implement and study the effects of providing Overdose Education and Naloxone
Distribution (OEND) in 2006. The OOPPP works with existing treatment programs such as
detoxes, inpatient treatment programs, and short- or long-term recovery housing, in order to
provide training and naloxone to at-risk individuals and potential bystanders (BSAS, 2012;
Doe-Simpkins et al, 2009).
In a 2010 survey conducted by the Harm Reduction Coalition, the OOPPP was one of
48 U.S. naloxone providers providing OEND at 188 sites (Wheeler et al., 2010). When the
same agency conducted a similar survey in 2014, that number had risen to 136 programs
serving 644 sites (Wheeler et al., 2015). Not only did the number of programs providing
OEND nearly triple over this time span, the geographical area that they covered increased
substantially as well: from 15 states and the District of Columbia in 2010 (Wheeler et al.,
2010) to 30 states and the District of Columbia in 2014 (Wheeler et al., 2015). In other words,
this four-year span did not just see naloxone become more accessible in states that had already
embraced OEND—it also saw OEND adopted in many states that had previously resisted it.
All together, these programs have distributed an estimated 150,000 naloxone kits and have
tracked over 26,000 opioid overdose reversals (Wheeler et al., 2015).
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CHAPTER III
LITERATURE REVIEW
The concept of “harm reduction” has been applied to injection drug use in many ways,
and encompasses a wide range of strategies. These include, but are not limited to, syringe
exchange, street outreach, supervised injection facilities, promoting non-injection routes of drug
administration, risk reduction education, “grass roots” organizing of drug-injecting peers, drug
purity testing, and naloxone distribution (Ritter & Cameron, 2006). What these interventions
have in common is that they aim primarily to reduce the harm associated with drug injection;
while they may not exclude working towards (short- or long-term) abstinence or decreased use,
these are not goals in and of themselves (Lenton & Single, 1998).
There is not much published research on the ways that narcan-based overdose
prevention has been incorporated into treatment and recovery settings, and a majority of
published articles focus on naloxone distribution in syringe exchanges, by street outreach
workers, and through peer recruitment channels.
In their discussion of a Wisconsin counseling program serving primarily substance using
women, Ackerson & Karoll (2005) report that that “incorporating a harm-reduction philosophy
within a traditional abstinence-based agency setting” was challenging for staff, both from a
clinical standpoint and in terms of collaborating with outside agencies who continued to adhere
to a strict abstinence-oriented framework. However, in this case “harm reduction” is
conceptualized primarily in terms of staff’s being open to helping clients work towards goals
other than full sobriety, and accepting the possibility of relapse as part of the recovery
process—there is no mention of taking active steps like providing naloxone to current or past
opiate users.
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In an email questionnaire, Hofschulte (2012) investigated Minnesota social workers’
attitudes towards harm reduction and towards substance users in order to determine whether
positive or negative attitudes towards either or both were connected to the clinicians’
demographic characteristics, professional history, or self-perception. She found that positive
attitudes towards harm reduction were associated with having worked with substance using
populations, having been trained on substance use and addiction, and perceiving this training
as adequate. On the other hand, only past training on substance use and addiction was
associated with belief in the efficacy of harm reduction-based treatment. None of the
measured factors were associated with positive or negative perceptions of substance users.
Koutroulis (2000) conducted a small qualitative study that explored the ways that
substance treatment staff understood and applied the concept of harm reduction. For the
purposes of this research, “harm reduction” was conceptualized primarily in terms of staff’s
being open to working towards goals other than full long-term abstinence, and willing to
provide education and resources that support safer substance use. She described an ongoing
tension between clients (who generally entered the program with the intention of ceasing
substance use) and staff (who often felt that it was safest to assume that their clients would not
be able to maintain abstinence). Some staff found it conceptually challenging to negotiate the
gap between ideal (abstinence) and reality (expected relapse), and therefore saw harm
reduction as a tool to be used when they judged a particular client to be at risk for relapse, or
unlikely to contine attending their program. Others saw no conflict between harm reduction
and abstinence, and consistently provided harm reduction information and counseling as part
of their baseline treatment. As with Ackerson and Karoll (2005), there is no mention of
providing naloxone to clients potentially at risk for opiate overdose.
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Maxwell et al. (2006) describe a Chicago-area naloxone distribution program similar to
the one implemented in Massachusetts, and report that it appeared to be effective: not only did
it result in 319 reported overdose reversals from 2001 to 2006, but the local rate of fatal
overdose declined during the first 3 years it was implemented after rising steadily for a decade.
This program provided naloxone via outreach vans, at fixed sites, and through a telephone
pager system, but did not contact opiate users in treatment or recovery settings. However, the
authors strongly advocate for expanding overdose prevention training and naloxone
distribution into detoxes.
In their interviews with a treatment sample of methadone clinic patients who had little
or no previous experience with naloxone, Strang et al. (1999) found strong support for
naloxone distribution as a way to decrease overdose fatalities. While 70% of this population
felt that distributing naloxone would be either a “good” or “very good” idea, only 13% felt that
it would be a “bad idea. Within that dissenting minority, less than half of felt that it might
encourage them to increase their opiate use. While this study did not address the views of
methadone program staff, it does suggest that there may be substantial interest in naloxone
among substance users who are in treatment or recovery.
Using data collected by the OOPPP’s programs in Massachusetts, Walley et al. (2013)
described the program’s success in training and enrolling nearly 1,000 opiate users from
methadone treatment and detox settings, which resulted in 33 reported overdose reversals from
2008 to 2010. These reversals were reported to staff by the trainees themselves after the fact,
either when they returned for more naloxone, or when they were seeking other services from
the OOPPP program that trained them. Therefore, this total would not count reversals
performed by opiate users who had no subsequent contact with program staff—perhaps
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because they stopped using, because they were able to obtain naloxone from other sources, or
because they left the area. Furthermore, it is possible that even trainees who did return to an
OOPPP program to get a naloxone refill might not have consistently reported overdose
reversals. For instance, they may have felt obliged to “protect” the people or places involved,
they may have believed that it was not their place to report the incident because they did not
directly administer the naloxone, or they may have forgotten the incident (or decided that it
“did not count”) because so much time had elapsed between the reversal and their next
program contact.
Walley et al. (2013) also outline five different ways that overdose prevention training
and naloxone were being provided to detox and methadone treatment patients:
1. Treatment program staff were certified to provide education and naloxone directly
to their patients.
2. Treatment programs hosted outside certified trainers to provide education
and naloxone to their patients.
3. Treatment program staff provided education, but referred their patients to one or
more off-site programs in order to receive naloxone.
4. OOPPP program staff conducted targeted outreach in order to provide
education and naloxone to detox or methadone program patients.
5. OOPPP program staff provided education and naloxone at sites not affiliated with
treatment programs
Of these categories, the first two will be especially relevant to this research project.
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CHAPTER IV
SIGNIFICANCE

As narcan distribution becomes more accepted as an effective way to reduce opiate
overdose fatalities, it seems likely that programs like OOPPP will expand. This is something
that I observed firsthand while working at the Cambridge Needle Exchange—at times it seemed
like the demand for narcan training was so high that the availability of certified training staff
was the only limiting factor. While narcan appears to have been enthusiastically adopted as a
life-saving strategy by state officials, harm reduction agencies, and opiate users themselves,
there appears to be a lack of research and data on the ways that it has or has not been embraced
by the staff of more traditional, recovery-oriented programs.
This is significant because these programs offer a valuable opportunity to reach opiate
users in an environment that is more structured than a typical street outreach or drop-in center
contact. Most detox, inpatient treatment, and recovery housing programs require their patients
to attend a regular schedule of groups and classes, and integrating OEND into this schedule
would ensure that the trainers have a physical space in which to conduct demonstrations and
enrollments, a set time in which to conduct the training, and a regular time and place for
trainees to participate—all of which may be lacking in more informal training settings.
Furthermore, recovery-oriented programs serve a broader demographic that includes individuals
who have stopped or intend to stop using opiates (Koutrolis, 2000), and who may not choose to
visit the social and physical settings where active users are more likely to be found. However, a
lack of staff buy-in may hamper efforts to expand narcan training into these types of programs.
Learning more about how these staff members assess the integration of narcan training into
their programs could improve the situation in two ways: first, by revealing areas where further
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training or resources would benefit them, and second, by suggesting ways that the narcan
distribution and training staff could improve their relationships with the programs that host
them.
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CHAPTER V
RESEARCH OBJECTIVES

In my experience as a needle exchange staffer and program manager I have
encountered a broad spectrum of reactions to the idea of offering naloxone training in
substance treatment settings. These reactions influence the ease or difficulty with which the
initial training may be scheduled, the amount of interest or disinterest with which staff
participate in the training, the extent to which they do or do not encourage patients to attend
patient trainings if they are offered, and the ease or difficulty of organizing further trainings,
naloxone distribution, or other follow-up meetings. I decided to explore this issue further by
conducting a study that addressed the following research questions:
1. Was the integration of OEND into recovery-oriented programs disruptive or
controversial? If so, why?
2. Did recovery-oriented program staff find it difficult to reconcile the harm
reduction philosophy underlying OEND with their personal and
organizational philosophies around substance use and recovery?
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CHAPTER VI
METHODS

This research project used a qualitative methodology, based on the principles of
descriptive phenomenology. This approach seeks to distill the essence of a phenomenon by
analyzing the description of individuals who have experienced it, and it has been found
especially useful when the phenomenon of interest has not been previously studied, or has
been only incompletely analzyed (Wojnar & Swanson, 2007). Since there is currently very
little published research on the integration of narcan and overdose prevention into addiction
treatment settings, the choice of descriptive phenomenology seemed appropriate here. This
methodology is based on the assumption that “there are features to any lived experience that
are common to all persons who have the experience” (Lopez & Willis, 2004, p.728), and this
study will use the lived experience of addiction treatment program staff as a window to learn
about the underlying phenomenon of integrating overdose prevention and harm reduction into
recovery-oriented treatment programs. However, in light of the opiate overdose crisis facing
many countries today, learning for its own sake is not the final goal of this study. Hopefully,
its analysis will help to inform future research and program planning efforts as well—a goal to
which descriptive phenomenology is well-suited (Wojnar & Swanson, 2007).
The integration of OEND into addiction treatment settings is experienced by at least
two distinct populations: the staff of the programs in question, and their patients. However,
conducting ethically sound research with patients (many of whom also belong to other
vulnerable populations) is beyond the scope of this project. Furthermore, the Massachusetts
Department of Public Health and OOPPP indicated that they would not support my attempting
such research at this time. Therefore, this study’s subject population consisted of treatment
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program staff only. Furthermore, since descriptive phenomenology dictates that researchers
learn about a phenomenon through those who have experienced it, this study restricted its
sample to treatment program staff who had themselves experienced the integration of OEND
into their programs. In other words, subjects were drawn from settings falling under the first
two categories of Walley et al.’s taxonomy (2013)—those in which the treatment program
staff were trained to provide OEND directly to their own patients, and those in which they
hosted outside trainers from OOPPP programs. It excluded treatment programs that
exclusively referred patients to other locations for narcan distribution, and where OOPPP
programs conducted outreach or recruitment, but did not actually provide OEND.
Since this study’s research questions both addressed the issue of whether the
experience of OEND integration was a positive one, it used a purposive deviant sampling
strategy based on how smoothly OOPPP staff and trainers felt that the integration process
went. This allowed the final analysis to incorporate perspectives from staff whose programs
embraced OEND (on an operational level, at least), as well as those whose programs resisted
it or found it logistically difficult to adopt. This approach allowed the study’s analysis to
develop a broader and richer understanding of the phenomenon, to “uncover […] the
boundaries of difference within [the] experience”, (Polkinghorne, 2005, p.141), and to
“illuminate subtle but potentially important differences” (Barbour, 2001, p.1116) between the
purposive sample’s sub-groups.
Although ideal qualitative sample sizes cannot be computed the same way that
quantitative ones can, there does appear to be a general consensus that descriptive
phenomenological studies can obtain useful data from relatively small samples (MaggsRapport, 2001; Omery, 1983). In fact, some research suggests that such studies may reach
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saturation—the point at which adding more data does not help researchers to develop new
categories, or to further refine the properties of those they have already identified—with
sample sizes of a dozen or less (Guest et al., 2006; Starks & Trinidad, 2007). Morse (2000)
states that studies with relatively narrow scopes may expect to reach saturation using smaller
samples. With that in mind, this study’s planned sample size was to be ten individuals,
interviewed one time apiece. Analysis of the interviews suggested that this was enough to
achieve saturation: several important themes appeared in all or nearly all the interviews, and
many themes were present in a solid majority of them. Even when themes encompassed
different perspectives, there was enough overlap between the subjects’ experiences for them
to confirm and complement one another. Based on this analysis, I would have expected that
adding more data (without altering the study’s sampling or selection process, as discussed
below) would have tended to confirm and reinforce the themes that were already appearing
consistently.
The sample was assembled as follows: each OOPPP program was asked to list the
treatment settings in which it conducts OEND trainings or where it has trained local staff to
conduct them, rating each one on a 1-3 scale according to how smoothly it integrated OEND.
The scale was intended to highlight the positive and negative extremes of the potential subject
pool, in accordance with purposive sampling practice:
1. The program requested OEND and was supportive of OOPPP staff
2. The program did not actively request OEND but was not resistant to it
3. OOPPP staff had to reach out to the program several times before they agreed to
host OEND, and/or found it challenging to collaborate with them
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I then reached out to potential subjects in order to assemble a ten-person sample. The intent
was to make sure that both extremes were represented in the study’s sample, so I attempted to
include at least three staff from programs that were rated “1” on the scale above, and at least
three from programs that were rated “3.” In practice, this was somewhat challenging as a
majority of the contacts I was given by OOPPP staff fell under the first category, which made it
difficult to schedule interviews with subjects from the second and third categories. In
particular, only 3 programs were identified as “challenging,” one of which did not respond to
participate, even after I made several attempts to contact them. Ultimately, the sample
consisted of 7 subjects from “supportive” programs (category 1), 1 subject from a “neutral”
program (category 2), and 2 subjects from “challenging” programs (category 3). This may
represent a limitation of the study, and will be discussed at more length in a later section.

Instrument
This project’s data collection instrument was an open-ended interview protocol. It
consisted of 11 main questions; follow-up prompts were sometimes used depending on the
depth and detail of the subject’s initial answer. The questions were sequenced to begin with a
background question, and then to proceed from concrete questions about the present, to
concrete questions about the past, and finally to more reflective questions.

1. What kinds of experience have you had in the substance abuse and addiction field?
a)

What positions have you held at [your program]?
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2. How do narcan trainings happen at your program? [If the answer does not appear to fit
into the five categories outlined in Walley et al., 2013 and cited in the Literature Review
section, subject will be asked to elaborate]
a)

How does [your program’s] staff decide when to schedule a narcan training?

b)

Which members of [your program’s] staff and patients go to these trainings?

3. What do the outside trainers do when they run a narcan training at [your program]?
4. What is your role when a narcan training happens at [your program]?
5. Think back to the time before [your program] started hosting narcan trainings. What
made [your program] decide to start hosting narcan trainings?
a)

What did you see as the pros and cons of narcan training before it started
happening at [your program]?

b)

What did you expect from the first narcan training at [your program]?

6. How did the first few narcan trainings go?
a)

What concerns did [your program’s] staff have about those first few narcan
trainings?

b)

What benefits did they see in hosting narcan trainings?

c)

How did your clients feel about those first few narcan trainings?

7. How are [your program’s] narcan trainings going these days?
a)

How would you say [your program’s] staff feel about narcan training now?

b)

How would you say your clients feel about narcan training now?

c)

How have these trainings affected your program, either positively or
negatively?

8. What are your goals when working with clients at [your program]?
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9. How does harm reduction relate to your work at [your program]?
10. Think about different kinds of harm reduction, like safer injection training, encouraging
drug injectors to switch to non-injection use, methadone and suboxone treatment, needle
exchange, safer injection rooms, or drug decriminalization.
a)

How do you feel about these things?

b)

What differences do you see between them?

c)

Which ones would you refer your clients to?

11. Is there anything that you would like to add about your experience integrating harm
reduction and narcan training?

Analysis: Theory
In addition to looking for shared elements and commonalities among these subjects’
experiences, the analysis was alert for variations between them in order to explore the ways
that overdose prevention training has been experienced differently among members of the
subject population. The descriptive phenomenology approach was chosen because, in the
absence of pre-existing research or analysis on this specific topic, it seemed most fitting to take
an open-ended look at the conceptual landscape before committing to a more closed,
quantitative methodology (Wojnar & Swanson, 2007).
One central element of descriptive phenomenology is the process of suspending or
bracketing prior beliefs or understandings that the investigator attaches to the phenomenon
being studied. This is done in order to help them remain open to whatever meanings emerge
from their subjects’ narratives, rather than forcing them to fit pre-existing theories or
interpretations (Hycner, 1985). Bracketing must be an ongoing process throughout this type of
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phenomenological investigation (Wojnar & Swanson, 2007). During the planning,
interviewing, transcription, and analysis phases of this study, I maintained a reflective
research journal in which I noted my own preconceptions and reactions concerning OEND,
addiction treatment and recovery, ways that I might have influenced subjects’ responses, and
any other issues that arose.

Analysis: Process
I digitally recorded the interviews. Immediately after each interview was complete, I
used my research journal to record any significant information that might not have been
captured on the audio recording—interruptions, time constraints, non-verbal communication,
or deviations from the normal interview protocol. In addition, I made note of any of my own
preconceptions or assumptions that may have come to light as a result of the interview. These
journal entries were used to facilitate accurate transcription, to give a stronger sense of the
meanings being conveyed, to improve my analysis of the narrative, and to ensure that
bracketing remained an ongoing part of the process.
Next I transcribed each interview verbatim, appending any notes taken after the
interview. When each transcription was complete, I re-read it as a whole, re-listened to the
original recording, and re-read it while listening to the recording. At this stage the intent was to
get a general sense, or “gestalt” (Hycner, 1985) of the meaning(s) being conveyed. I continued
to record my observations and impressions in my research journal, along with any of my own
preconceptions or assumptions that may have come to light.
Before starting the coding process, I entered the interview transcripts into the QDA
Miner qualitative analysis package. I used this software to track and record codes, and to cross-
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reference them between interview transcripts. I coded the interview transcripts using an
iterative process, first by open-coding to look for recurring and salient themes, and then by recoding them once I had developed a final list of coding categories (Hycner, 1985). As I
created, combined, and eliminated categories I documented my decision-making process in my
research journal. In doing this I focused on building a picture of how the subjects had
experienced the process of incorporating naloxone distribution into their work. To do so, I
used information that they provide explicitly (for instance, in response to questions 6 or 7), but
I was sensitive to the language that they used when answering questions that addressed the
topic less directly (such as 3, 4, 8 or 9).

Analysis: Establishing trustworthiness
Guba (1981) suggests that the “trustworthiness” of qualitative research be assessed in
terms of how well it fulfills four criteria: truth value (i.e. how accurately it depicts the
experience of its subjects), consistency (i.e. the extent to which the study’s results would be
similar if it were repeated with other subjects in a similar setting), neutrality (i.e. the extent to
which the study’s results are a function of its subjects’ experience, and not its researchers’),
and applicability (i.e. how well its findings can be used to understand the experiences of other
subjects in similar settings). Some strategies for establishing trustworthiness along the first
three axes include member checking and peer debriefing (for truth value), maintaining an
“auditable” diary of research decisions (for consistency), and reflexively documenting the
bracketing process (for neutrality) (Guba, 1981; Hycner, 1985; Moore et al., 2002; Wojnar &
Swanson, 2007). The fourth axis, applicability, may be “more the responsibility of the person
wanting to transfer the findings to another situation or population than that of the researcher of
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the original study”—the original researcher’s job being to provide enough descriptive detail to
make this transfer possible (Krefting, 1991).
I established this study’s truth value by debriefing and discussing category coding with
a fellow researcher who has experience with qualitative research, in order to test my
perceptions and open my interpretations to their questions (Guba, 1981; Hycner, 1985). The
researcher in question was Jenn O'Neill, a licensed MSW and current PhD candidate at Lesley
University. She has worked on qualitative research projects in the past, and was an AIDS
Action Committee program manager during the time I was managing the Cambridge Needle
Exchange. She served as interim supervisor for the needle exchange staff after my departure,
and has a good deal of experience around opiate addiction and overdose.
In addition, I conducted member checks with two of the ten subjects after their
interviews have been transcribed and coded, in order to make sure that the themes I have
derived from their interviews have faithfully captured the essence of their experience (Guba,
1981; Hycner, 1985). In both cases, they reported that my summaries felt accurate to them. I
established consistency and neutrality by maintaining a research journal to document the initial
assumptions I had bracketed before beginning to conduct interviews, my subsequent reactions
to the interviews themselves, and my decision-making process as I created, combined, and
eliminated coding categories (Krefting, 1991). I also used this journal to document the
feedback I received from peer researcher debriefings and member checks, and to track the
ways I incorporated this feedback into my ongoing analysis.
Finally, I made sure that it was clear at all stages that my intent was not to “evaluate”
the programs whose staff I interviewed, nor to report the material details of how they have
implemented overdose prevention training. I discussed this with each subject before beginning
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the interview, and with other staff or supervisors with whom I spoke in the process of
scheduling the interviews. I emphasized that all data included in my final analysis would be
stripped of personal and program names, as well as any details that might identify a particular
individual or program.
When my analysis is finalized, I will present the results at a quarterly meeting of the
Massachusetts OEND pilot program. I will also create a more streamlined write-up of my
results that is suitable to be shared with the staff at the programs where my subjects work, or
even with those working at other treatment programs with an interest in OEND.
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CHAPTER VII
RESULTS

Ten subjects were interviewed. There were 7 women and 3 men, with 1-26 (average 9,
median 5.5) years' experience working in the addiction field. The analysis process uncovered 4
broad thematic domains in the interview subjects' experiences, each of which encompassed
several parallel or contrasting themes:
Thematic domain

Themes

What is overdose prevention training?

Overdose prevention training is education
Overdose prevention training is a narrative

What is narcan?

Narcan undermines recovery
Narcan is part of a regular life routine
Using a narcan kit is frightening
Narcan saves lives

What is harm reduction?

Harm reduction means using drugs more safely
Harm reduction is a means to an end

What is the goal of treatment?

The goal of treatment is abstinence
The goal of treatment is survival
The goal of treatment is up to the client

When I have quoted them below, I have referred to them by number based on the order in which
they were interviewed.

Subjects' perception of overdose prevention trainings: Overdose prevention training is
education
This theme was the only one to be recorded at least once in every interview. Subjects
generally mentioned it in a neutral, factual manner.
Clients leave here with […] new information, upgraded information. -S10
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I think that they appreciated, you know, the information. -S7
However, two subjects returned to this theme again and again, in one case 18 times in the course
of the interview. For them, the notion of overdose prevention training as education is of great
significance.
So I think the biggest thing is definitely the education the clients get. -S1,
emphasis added
And for one particular subject, this kind of education is seen as a societal good that transcends
the narrow setting of the training sessions and their specific audience of addiction treatment
program clients.
And I think education is really important. And I'm glad to see, like I said, it's
starting to come out on the TV and stuff like that. -S3
We need a lot of education. You know, I talked to one of the police officers—we
went to […] drug court graduation—and he says, you know, he's big on helping
parents and educating them, which I think is wonderful. -S3

Subjects' perception of overdose prevention trainings: Overdose prevention training is a
narrative
In contrast, this theme was not as widely recorded, and was not mentioned as often
among those subjects who brought it up. However, it elicited detailed responses from a few
subjects:
We had one instance where [the client] left the facility, went right up to Dunkin
Donuts, and used [a narcan kit]. Cause she found somebody in the bathroom.
Right up the block. […] So that kinda hit hard for the people that were sitting in
the group, it was nice. -S8, emphasis added
[The trainer] really goes into detail, he's really good about: 'Let me get through all
this information and then ask the questions after.' [...] Our clients, not that it's a
bad thing, but some get very open, and they feel like they need to disclose
information, so if he starts getting off track you have all these different
conversations going on. -S8, emphasis added
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The trainings are seen as proceeding along an educational “track,” but with the ever-present risk
of being derailed by narrative and storytelling. While this can impede their educational function,
it may also have positive value if it elicits an emotional response in the training participants.
The notion of narrative overlaid on top of education was articulated more explicitly by
another subject:
I thought it was gonna be just: I'm gonna educate them, and it might be that I
would be lecturing and they would be sitting, listening. And it's not like that at all.
-S2, emphasis added
They don't just sit like they're bored—they wanna talk about the losses that
they've experienced in their lives and the people they knew that have overdosed. S2, emphasis added
This repeated use of the word “just” suggests a contrast between the overdose prevention
trainings' baseline educational component, and the narrative component that allows them to rise
above that baseline (and the boredom that it entails).

Subjects' perception of narcan itself: Narcan undermines recovery
While this theme was recorded in a majority of the interviews, it was typically addressed
obliquely and not as something that directly characterized the subjects' own current perception of
narcan. For instance, for some subjects the idea that narcan might undermine recovery was
relevant not primarily because they themselves thought it was true, but because they knew that
other people did.
It's interesting to bring [narcan] into a program where people aren't supposed to be
using drugs. But some do. So a lot of patients were like, 'Well why are you giving
me this? I don't use drugs anymore!' -S7
I think the only negative thing is about, you know, just the perception of [narcan]
and, you know, if it undermines their recovery or not. Some people think it might
undermine it. -S1
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Other subjects brought up this theme as something that had shaped their perception of narcan in
the past, but that was not part of their current view.
I did think [before being directly exposed to narcan trainings], 'I wonder if this
isn't a good program, because does it encourage them to wanna go out and use
opiates with their friends, knowing that they have a way to bring back or
resuscitate a friend that...overdosed?' Now that I know more about it and I'm more
educated, and I talk to the clients weekly about it I realize that it's saving lives. I
no longer feel ambivalent about it, I feel strongly that it should be in the hands of
those that use drugs, and it should be back at the homes of their families, and I
completely—now that I know more about it—am a total advocate for it. -S2
In fact, some of the subjects who mentioned that they had previously seen narcan as something
that undermined recovery explicitly argued against this notion based on their current perception
of narcan.
At first […] you think you give [narcan] to 'em, you give them the okay to use.
Well you know what, that's ridiculous. They're gonna use if they're gonna use. -S3
When we first started [narcan trainings] back in 2008, some of my behavioral
health staff were a little leery about it because they felt that we were enabling
people to use by making narcan available. [“And how did those first few trainings
go?”] They went fine because once they got the information they opened their
eyes to the flipside of it. And it's not, you know, we're not trying to—I mean,
people are gonna use no matter what. People aren't thinking 'Oh gee, it's okay for
me to use now because I know there's narcan hangin' around.' -S4

Subjects' perception of narcan itself: Narcan is part of a regular life routine
When this theme appeared, it was often in very personal and immediate terms. In fact,
nearly half of the interview subjects volunteered that they personally carried narcan with them
outside of professional settings.
I carry it in my glovebox all the time. -S9
I even have narcan in my truck, I have narcan at my house. So if something
happens I have narcan. -S10
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For several subjects, this attitude carries over into their interactions with clients, who they also
encourage to incorporate narcan into their lives whether or not they are actively using opioids.
I tell the clients that […] 'if you can carry your drugs on you, why not carry the
narcan?' -S1
At one point, before we knew much about it we didn't allow it but we definitely
allow it now and […] even if they don't wanna sign up we're kinda like 'You
know, you might be at a stoplight, you could help somebody.' -S3

Subjects' perception of narcan itself: Using a narcan kit is frightening
This theme was also fairly common, appearing in half the interviews—generally among
the subjects who did not report carrying narcan on their person outside of work. The main source
of fear and anxiety tended to be the narcan kit itself. This was partly because it superficially
resembles a syringe, which the subjects strongly associated with injection drug use.
At first we were a little wary about it, cause it's new and it looks terrible. I mean it
looks like a syringe. -S3
My first thought was, 'Oh, it's a shot? We're not gonna give a heroin addict
needles!' -S8
In addition, some subjects saw the narcan kit as intimidating in its complexity, especially as they
imagined trying to assemble it under the stressful conditions of a real overdose.
[The narcan kit] looks a little intimidating I guess—put yourself in a situation,
you know. I think it could be a lot easier to use. [“How so?”] I just feel like there's
a lot of little things you have to do, you know, put certain parts here [...] I just feel
like maybe in a situation with something going on like that, myself I'd be really
shaky, and like, you know, trying to rush. And, you know, if it all came together
already I just think it would be a lot quicker. But I've never had to use narcan on
anyone. So I don't know really how it is in that situation, it's just me imagining. S6
I think in the back of everybody's mind even including myself: 'God forbid I have
to use it,' and 'I'm not confident using it,' and you know, fear is there. Because,
number one, because of how you have to put 'em together and everything—you
have the mechanics of what's involved before ever hittin' somebody up with it. S9
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Not only is the narcan kit itself frightening due to its complexity and resemblance to a syringe,
but several subjects were afraid that opioid users would react with anger or hostility after being
given narcan.
I also let 'em know that when you take them out of that overdose, they can be
angry. And they can be violent so you have to be careful with that. -S3
I have heard from clients before that when they're narcan-ed they get mad.
Because their high goes away. -S6

Subjects' perception of narcan itself: Narcan saves lives
This theme appeared frequently and in most of the interviews. In some cases it referred to
specific, concrete events.
I saw a client on the outside and they told me, 'I died and like, I got brought back
because of narcan.' -S5
I had a client this morning who was here prior, he got the narcan here and before
he left the program he said he ended up using with a friend, actually somebody
that he met here. The friend overdosed, he had the narcan on him, hit him with
narcan, saved his life. [...] I also shared a story with a client: I know this lady
who's a social worker, who was leaving the gym and she seen this lady in the
parking lot, shaking her husband and he was overdosing. She had narcan on her
cause she was recently trained, she had a narcan in her car—hit him with narcan,
saved his life. -S1
At the narcan group yesterday when two clients raised their hands and said, 'Can I
talk to you? That narcan you put in my suitcase, I saved my little brother.' -S2
It was notable that even when they described narcan saving a particular life, the subjects were
speaking about an overdose reversal that had been performed by a client, a friend, a co-worker,
or a casual acquaintance—none of them described a situation in which they were the one to use
narcan on an overdose victim.
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Several other subjects emphasized this theme with no reference to a particular life-saving
incident. For them narcan saves lives, and has the potential to continue saving lives, primarily in
the abstract.
[Narcan] saves lives. I mean it kinda speaks for itself, it's a no-brainer as far as
I'm concerned: it saves lives. -S9
While you're in the program, you're gonna get this training, and you're gonna get
this medication that you can use to save someone, or someone can use to save
you. -S7
[Clients] leave here with the opportunity, even though they hope they don't have
to use it, to save one of their peers' lives. -S10

Subjects' perception of harm reduction: Harm reduction means using drugs more safely
Although this was a less common theme, it did appear in over half the interviews. Some
subjects acknowledged it indirectly, by providing examples of the kinds of advice they give to
their clients:
So I educate them as part of the narcan training, 'If this is not your last detox, and
we hope to see you again—if this isn't it for you, there are things you can do to
protect yourself from overdose before narcan might have to be used on you. Such
as: don't use the amount that you used when you leave here. Use a tester shot.
Know your drug dealer. Know that what you buy in the streets, what it is. Um,
know and trust your drug dealer.' -S2
I'll let them know, 'You know you should have the non-emergency line in there.
That way you're not having police involvement. […] You know if you don't
wanna call the police you can the ambulance instead. And if you do call the police
you should just tell 'em that they're not breathing. That's it, you don't have to say
anything else.' -S3
They may not explicitly tie these examples to a broader philosophy of harm reduction, but that
philosophy is implicit behind their attempts to help their clients use opioids more safely, by
avoiding hazards such as overdose and contact with police officers. Other subjects expressed
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their views on this theme more directly, with one of them even using the harm reduction trope of
“meeting people where they are at”:
I mean, I think that you have to meet people where they're at. So, some people
aren't ready to stop using drugs, so if we can help them use in a safer way, then
that's a step in the right direction. -S7
[Harm reduction] is just integrated into [the work we do here] because we realize
that, that people are gonna, people are gonna relapse—it's gonna happen. And our
responsibility is to provide 'em with the tools and the resources they need, that if
they do relapse, they don't die. -S4
I just have come to see [harm reduction] as an integral part of what we do. I don't
think we can do treatment without some degree of focus on, on harm reduction. S4, emphasis added

Subjects' perception of harm reduction: Harm reduction is a means to an end
This theme was even less common, but was interesting for being closely tied to the more
direct and explicit endorsements of harm reduction described above.
Sometimes we use, we use the harm reduction model with patients who need to
come to the clinic, and so we kind of use the suboxone program as a way to get
them in here for their other care. You know, for patients who are HIV positive,
who need to see an infectious disease doctor, who need medication adherence
counseling. So we'll kind of use, use the program to our benefit in that way. […]
They wanna come for suboxone, cause they know they're gonna get the suboxone.
They don't wanna come and see their infectious disease doctor, if they're not
getting anything out of it. -S7
I think harm reduction has its place even in abstinence-based treatment cause the
reality is, people relapse and we need to keep them alive. And that's all we're
trying to do at this point: keep 'em alive so we can get 'em into treatment. -S4,
emphasis added
Whether the end goal is a broad one like “get clients back into treatment” or a more specific one
like “get clients connected to medical services that they wouldn't be motivated to seek out on
their own,” here harm reduction is perceived as a tool that helps the subjects to achieve goals
other than reducing the harm of opioid use. It was striking that this theme was most clearly
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articulated by the same subjects who had most strongly expressed positive views of harm
reduction in the broad, philosophical sense.

Subjects' perception of addiction treatment: The goal of treatment is abstinence
This was a common theme, and appeared in nearly all the interviews. In many cases the
subjects acknowledged that they saw the goals of treatment as being complex and multi-faceted,
but went on to assert that abstinence occupied a privileged place as the most important goal, or
the most consistent, or the one that had to be in place before others could be addressed:
I can't micromanage them but I can offer them all the support, aftercare in
whatever community they live in—I will call veterans' groups if it's a veteran, I
will call anyone I know with a contact anywhere to help them. Call someone at an
AA meeting, 'Can you meet them at this group, cause they're afraid to go into a
new group.' The best call I ever get is when someone calls back to say, 'Will you
come see me get my [AA] medallion?' -S2, emphasis added
In the back of my mind, I don't know if this is wrong or right, but I always have
the ultimate goal of total abstinence [...] But if it's not their goal, it doesn't fly. But
that's always the hope: to have a drug free, um, dependence free lifestyle. -S9,
emphasis added
I mean, the big picture is we want them to, you know, abstain from drugs and,
kind of, become more active participants in the community. So we really
encourage people, like when they're doing well, like, 'Well how about, you know,
we start looking for employment, or volunteering, or, um...' You know, so those
are our goals: for people to get clean, and then, like, be able to better themselves
other ways. -S7, emphasis added
In some cases the subjects so strongly saw abstinence as the primary goal of treatment that they
discouraged clients from seeking out harm reduction resources that they felt might undermine it:
I believe that if you're gonna be clean, be clean. But again, [suboxone] works for
some people. Some people can do it and some people cannot. So...Again I'm open
for anything that works for you. I would like you to try this road first, this clean
road with nothing. Drop the suboxone, drop the methadone if you can—try that
first, you know? -S3
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I personally don't agree with teaching somebody, you know, different ways to,
you know, shoot up or, you know, use needles like that. I don't agree with those
things, I kinda feel like we're telling them, it's like an enabler I guess. -S6
There are places we refer clients to that are harm reduction programs, that they
aren't as strict and structured and they don't get urine tested. And some clients
wanna go out cause they figure, 'Oh I'll use but not as much.' And I hesitate to
send clients to some of those programs, because I feel like I'm setting them up for
failure rather than success. -S2

Subjects' perception of addiction treatment: The goal of treatment is survival
Just over half the subjects saw the goal of addiction treatment as being, in part at least, to
help clients stay alive even if they were not able to maintain abstinence:
But if they don't have [access to clean syringes], they may die. And let's give them
something to keep them safe for that day, the next couple days, until they realize
what they need. -S8
Keep 'em sober, keep 'em safe. Um, educate them. Let 'em know there's help, if
they need it. Um, if they relapse it's not the end of the world. We can help. You
know, come back, let us know, call us, tell us—we'll help you. They always worry
that, you know, when they relapse we're mad at them. I'm like, 'We're not mad at
you. You know? We wanna help you.' -S3
For most subjects, this theme appeared alongside the previous one (that the goal of treatment was
abstinence). Some alluded to a hierarchy of goals in which abstinence was ranked more highly
(as described above), but for others the two goals coexisted without either one being prioritized.

Subjects' perception of addiction treatment: The goal of treatment is up to the client
Half of the interview subjects brought up this theme. As was the case with the previous
theme, when the notion of client-set treatment goals was mentioned, it was usually contrasted
with the subject's view that the proper goal of treatment was sobriety.
In the back of my mind, I don't know if this is wrong or right, but I always have
the ultimate goal of total abstinence [...] But if it's not their goal, it doesn't fly. But
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that's always the hope: to have a drug free, um, dependence free lifestyle. -S9,
emphasis added
We're very client-centered in our treatment. So...it's really about their goals, not
ours. Um...and what they're looking for. And the needs of the population that we
serve are so complicated, so much more complicated than they used to be years
ago. [...] I mean there's just like a whole laundry list of things, and the challenge
in treatment and what we want to help clients do is to learn to prioritize what
comes first, and tackle each piece step by step. Obviously we wanna encourage
them to be abstinent but we can't make that decision for them, so it's really about,
our treatment focus is really about personal empowerment. -S4, emphasis added
I think they're just different levels [...] Teaching someone to, you know, clean
their needles is different, you know, that person's just at a different level than
someone being on methadone or suboxone, ready to stop using drugs altogether. S7
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CHAPTER VIII
DISCUSSION

What is overdose prevention training?
Although they took place in a range of settings, involving different client populations and
staff with widely varying degrees of experience, the overdose prevention trainings themselves
were consistently experienced as an educational exercise first and foremost. This is not
surprising, given the trainers' need to convey information and key concepts within the time and
logistical constraints of treatment programs such as these. However, some subjects also
experienced these training sessions as a space where clients and staff shared and processed their
experiences surviving overdose, rescuing others from overdose, and losing friends and loved
ones to overdose. Some subjects felt tension between the trainings' educational format and their
clients' desire for narrative communication and emotional catharsis. However, even when they
described this as filling a need that education alone could not, they did not discount the value of
education. Rather, education was seen as the foundation of overdose training, and narrative as
the element that strengthened and filled gaps in that foundation.

What is narcan?
Subjects perceived narcan itself in many ways, some of which appeared to be at odds
with each other. For instance, the narcan kits themselves were intimidating and complex to
many, and the process of using them was imagined to be frightening, but narcan was also seen as
something that should be part of everyday life—carried not just by active injection drug users,
but by anyone who might come across an overdose in any public location. Narcan is seen as lifesaving, but also as something that can easily be misconceived as promoting drug use.
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Significantly, compared to the other themes found in this study, the subjects experienced narcan
through a lens of external and indirect factors—memories of their own past opinions,
assessments of other people’s beliefs, hypothetical fears, and accounts of other people’s
experiences. Their own direct experiences with the kits themselves, with overdose reversals or as
overdose victims, were presented as a relatively small piece of the picture. Perhaps this theme’s
inconsistencies are a result of this lack of firsthand experience administering or receiving narcan
in an actual overdose situation.

What is harm reduction?
When the interviewer mentioned a range of harm reduction strategies, some subjects
responded in broad emotional terms, with little or no emphasis on their particular experience or
reasoning. This general emotional reaction could be negative:
I am not a fan of it. –S5
I mean I just feel like when you're teaching them things like that, we're just
showing them new ways, you know, do you understand what I'm saying? […] I
don't even know. I just, I don't know—I'm just not a fan of things like that. I feel
those are negative things I guess. –S6, emphasis added
But it could also be positive:
[“What sorts of differences would you see between these different types of harm
reduction strategies?”] I really don't see any differences, I'm seeing a lot of
similarities. I mean, it's all like I said: it's all a form of reducing harm. It's a
beautiful thing—nobody's out to hurt anybody, we're all trying to help keep folks
alive. So it's a common bond and that's what stands out for me, is not—I don't see
any differences. –S9, emphasis added
While some subjects painted harm reduction with a broad brush as “negative things” or
“a beautiful thing,” others recounted a more specific experience of the concept as it related to
their work. They understood and implemented harm reduction as a way to help their clients
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remain safe (from physical harm, from incarceration) while they continued to actively use drugs.
Even when this philosophy was not explicitly articulated, it was clearly implicit in the
interactions that these subjects described having with their clients, both in and outside of
overdose prevention training sessions. Keeping clients safe and alive was presented as the selfevident end goal of harm reduction, but sometimes it also served as a way to accomplish
additional goals, such as getting clients back into treatment or connecting them with medical
care. In other words, they experienced harm reduction as an integrated part of treatment, rather
than as a discrete safety-providing mechanism that could be added or subtracted from their work.

What is the goal of treatment?
Clients’ abstinence from drug use was strongly felt to be the primary goal of treatment.
However, many subjects also acknowledged other goals, such as helping clients to remain safe
and alive, or supporting goals that the clients set for themselves. When subjects felt that these
goals were in conflict, abstinence was often the priority. Even when they had otherwise
expressed support for harm reduction, they did not see it as something that could be weighed
against abstinence—the conflict was essentially one-sided, with abstinence the a priori winner. In
a sense, they did not experience the conflict between goals as a “conflict” at all, since the
outcome was a foregone conclusion. However, there were times when the goals of treatment
were seen as less hierarchical, with clients’ safety, sobriety, and self-determination as mutually
complimentary rather than opposed to one another. To some extent, this perspective was more
characteristic of subjects who had a more integrated view of the relationship between treatment
and harm reduction (see “What is harm reduction?”, above), but the two themes did not overlap
exactly.
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CHAPTER IX
LIMITATIONS

When assembling a sample population, my original intention was to strike a balance
between subjects who came from programs that seemed to be supportive and receptive to
OEND, and those who came from programs for whom OEND had not been as smooth a fit—
in other words, to sample purposively in order to capture a range of perspectives. This
intention was to be implemented by asking the OOPPP contacts to place each of their partner
programs (i.e. the sites where they conducted OEND training sessions, and from whose staff
my sample population would be drawn) in one of the three following categories:
1. The program requested OEND and was supportive of OOPPP staff
2. The program did not actively request OEND but was not resistant to it
3. OOPPP staff had to reach out to the program several times before they agreed to
host OEND, and/or found it challenging to collaborate with them
When I reached out to potential subjects, I attempted to include at least 3 from programs that
were rated “1” on the scale above, and at least 3 that were rated “3.” Unfortunately this proved
to be impossible, because a majority of the contacts I was given by OOPPP fell under the first
category, while only a small minority (3 total) fell under the third. The final 10-subject sample
included 7 subjects from the first category, 1 from the second, and 2 from the third.
Technically, this is very close to my stated goal: if a single subject from the first or second
category was replaced by one from the third, the final sample would have met the criteria
established at the outset. However, it is difficult not to see this sample as strongly skewed
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towards programs supportive of OEND, according to the spirit as well as the letter of my
sampling strategy.
I suspect this may have been caused in part by self-selection, whereby programs whose
leadership and/or institutional culture were most supportive of OEND were more likely to host
trainings more often and build relationships with OOPPP staff, which led them to be
disproportionately represented in my pool of potential subjects. Conversely, programs that
resisted OEND may have self-selected out of that potential subject pool by hosting trainings
irregularly or infrequently, and failing to establish the kinds of relationships that would have
led my OOPPP contacts to suggest them as interview subjects. It is also possible that programs
which found OEND challenging for logistical reasons (such as understaffing or staff turnover)
found participation in this study challenging for the same reasons—while no programs declined
to participate outright, there were several with whom I was unable to make contact after
repeated attempts, or with whom I was not able to schedule and conduct an interview even
after establishing contact. In fact, this was the case with the one “challenging” program whose
staff I did not interview. Finally, although I did my best to make it clear that I did not intend to
judge or evaluate the programs they were putting me in touch with, it is possible that my
OOPPP informants were reluctant to place an arguably negative label like “challenging” on a
program with which they were collaborating. This could have resulted in a programs being
described as more supportive than they actually were, and made it difficult to assess how well
my purposive sampling protocol had actually been implemented.
In hindsight, there are several strategies that might have mitigated the above limitations
of my study. For instance: I could have recruited subjects from programs that had previously
hosted OEND but were no longer doing so, in the hopes that this would give me a larger pool
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of potential subjects from challenging or OEND-resisting programs. I could have provided
individual- and/or program-level incentives in order to make participation more attractive to
programs facing staffing or organizational challenges. And finally, I could have framed my
sampling strategy differently, in order to avoid making key informants feel less like they were
passing judgment on their collaborators. Unfortunately, it was not possible to employ any of
these strategies “on the fly” as I was conducting this study—the first would have represented a
significant change in the study, the second would have required resources that were not at my
disposal, and the third would not have been effective once my informants’ perception was
colored by the (perhaps loaded) way the question was initially asked.
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CHAPTER X
CONCLUSIONS
My first research question was “Was the integration of OEND into recovery-oriented
programs disruptive or controversial?” Based on analysis of these interviews, I have concluded
that these subjects have not experienced the introduction of OEND as disruptive. On the few
occasions when they did mention disruption, the subjects felt that their clients’ need for catharsis
and personal engagement were not being met by the trainings’ over-emphasis on strictly
educational content. They did not experience this as a failure of the trainings (or trainers), or as
poor conduct by their clients, but rather as an opportunity to enhance the trainings by
strengthening their narrative component. Future OEND programs may benefit from explicitly
acknowledging the importance of narrative, and creating space for staff and clients to share
personal experiences and real-world examples to illustrate and complement their more traditional
educational content.
The subjects also did not experience OEND training as a controversial topic. When they
did allude to controversy, they situated it outside of their own current experience—either a thing
of the past, or a characteristic of other people’s beliefs. These controversies were resolved by the
subjects and/or their coworkers gaining a greater understanding of the issues around narcan and
overdose, or by conversations in which the subjects successfully defended OEND to skeptics.
This suggests that even it situations where OEND seems controversial in the abstract, the
controversy may dissipate once staff members have gained a better understanding of the
underlying issues, and have seen the training and tools provided firsthand. Communities and
programs that are considering the adoption of OEND can take comfort in the fact that whatever
controversy they initially face is unlikely to be deep-seated or long-lasting.
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My second research question, however, was more challenging: “Did recovery-oriented
program staff find it difficult to reconcile the harm reduction philosophy underlying OEND with
their personal and organizational philosophies around substance use and recovery?” Although
they overwhelmingly supported OEND itself, and tended to speak positively of “harm reduction”
in a non-specific sense, many subjects engaged with harm reduction (as a philosophy, but also as
a set of strategies) in fairly limited ways, especially when it threatened to encroach on the notion
of abstinence as the primary goal of treatment. In these situations, they tended to unilaterally
prioritize abstinence. Some experienced this as an emotional conflict, and expressed negative
views of harm reduction in this context; others simply took for granted that harm reduction
would give way to abstinence, but did not hold any negative feelings towards it. In both cases, it
seems that these subjects did indeed find it difficult to reconcile harm reduction with their
personal beliefs about abstinence—or perhaps, that they did not feel as if the two needed to be
“reconciled” at all, since it was a foregone conclusion that abstinence-oriented philosophies and
practices would trump harm reduction.
For advocates of harm reduction, this finding has both positive and negative implications.
On the one hand, it appears that OEND can be integrated into environments that are not receptive
to harm reduction in a broader sense. In other words, OEND is an effective and widely
acceptable way to reduce overdose fatalities now, without having to wait for a resolution of the
larger philosophical questions around harm reduction. On the other hand, in spite of its
effectiveness, OEND may not be a particularly good way to introduce harm reduction into
settings that had previously resisted it—precisely because OEND is so concretely effective and
uncontroversial, it is easy for staff to mentally separate it from the more abstract and challenging
issues that make harm reduction unpalatable to them. If “bringing harm reduction into recovery-
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oriented settings” is seen as a secondary goal of OEND, there may remain work to be done even
if OEND is successfully implemented on a wide scale. Indeed, it might be useful to further
investigate the way other harm reduction strategies are understood and experienced in settings
like these, in order to learn whether it is realistic to expect that resistance to them can eventually
be overcome the way resistance to narcan was in this study (i.e. by exposure and education), or
whether the relatively rapidly acceptance of narcan should be seen as a special case. In other
words: is the growing acceptance of narcan something that can eventually be replicated with
other harm reduction strategies, and if so what will need to be done in order to make that happen
more readily than it has among my subjects?
Although some subjects experienced harm reduction (aside from OEND) mainly in the
abstract, others did describe a work environment where harm reduction had been reconciled with
abstinence-based treatment philosophies. For them, harm reduction was more concrete than it
was for the subjects mentioned above, with more clear and explicit connections to the ways they
helped their clients. For instance, integrating harm reduction into their workplace might mean
focusing on client-selected goals other than abstinence, or helping clients to more safely use
drugs when they were not prepared to stop—in other words, they sometimes prioritized harm
reduction over abstinence. They did not experience this as a negative thing, even though they felt
that ultimately, abstinence remained at the core of their personal and organizational philosophies.
Harm reduction was not viewed with suspicion, or mere tolerance, or as something that was only
applicable in specific limited circumstances. Rather it was an integral part of their treatment
landscape—a landscape that was too complex to be explored through a strictly abstinence-based
lens. In the words of one subject:
I just have come to see [harm reduction] as an integral part of what we do. I don't
think we can do treatment without some degree of focus on harm reduction. -S4
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Because this study focused on its subjects' experiences, rather than issues of cause and effect, it
does not show how these programs' acceptance of harm reduction was or was not a result of their
implementation of OEND. Perhaps a future study could focus on this issue more specifically, and
attempt to establish whether there are lessons that can be learned from programs like these. A
prospective study might be especially useful here, in order to learn whether in addition to its
primary goal of reducing overdose fatalities, OEND has had a positive effect on some program
staff's willingness and ability to embrace other harm reduction strategies. If this does turn out to
be the case, it would be very interesting to explore what makes these programs and staff different
from the ones mentioned earlier, for whom the acceptance of OEND did not lead to a broader
integration of harm reduction into the workplace.
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